An intervention with access to C-reactive protein rapid test reduces antibiotic overprescribing in acute exacerbations of chronic bronchitis and COPD

Family Practice

Volumn 32, Issue 4, 2015, Pages 395-400

  Strykowski, David F ^a   Nielsena, Anni B S ^a   Llorb, Carl ^b   Siersmaa, Volkert ^a   Bjerruma, Lars ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Antibacterial agents; C reactive protein; Chronic obstructive pulmonary disease; Drug prescription; Drug therapy; General practice; Respiratory tract infections; Therapeutic use

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT;

AGE; AGED; ARTICLE; C REACTIVE PROTEIN RAPID TEST; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GENDER; GENERAL PRACTITIONER; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROTEIN ANALYSIS; RISK ASSESSMENT; SPAIN; UNDERPRESCRIBING; ACUTE DISEASE; BRONCHITIS, CHRONIC; CLINICAL PRACTICE; DISEASE COURSE; ODDS RATIO; PREVENTION AND CONTROL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; GENERAL PRACTITIONERS; HUMANS; INAPPROPRIATE PRESCRIBING; LOGISTIC MODELS; MALE; ODDS RATIO; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPAIN;

EID: 84939541797     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmv020     Document Type: Article

References (21)

1. Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J. 2010; 36: 758-65.
2. Llor C, Bjerrum L, Munck A, et al. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice. Ther Adv Respir Dis. 2013; 7: 131-7.
3. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002; 8: 278-82.
4. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease:phenomenon or epiphenomenon? Proc Am Thorac Soc. 2004; 1: 109-14.
5. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl Res. 2012; 159: 228-37.
6. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease.. Cochrane Database Syst Rev. 2012; 12: CD010257.
7. Canadian Thoracic Society (CTS). 2008 Update CTS Guideline - Highlights for Primary Care - Recommendations for Management of COPD. http://www. respiratoryguidelines.ca/COPD-2008-update (accessed on 6 April 2015).
8. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: http://www.goldcopd.org/ (accessed on 6 April 2015).
9. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196-204.
10. Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 716-23.
11. Hopstaken RM, Muris JW, Knottnerus JA, et al. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract. 2003; 53: 358-64.
12. Siddiqi A, Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2008; 3: 31-44.
13. Bjerrum L, Munck A, Gahrn-Hansen B, et al. Health Alliance for prudent antibiotic prescribing in patients with respiratory tract infections (HAPPY AUDIT) -impact of a non-randomised multifaceted intervention programme.. BMC Fam Pract. 2011; 12: 52.
14. Llor C, Cots JM, López-Valcárcel BG, et al. Interventions to reduce antibiotic prescription for lower respiratory tract infections: Happy Audit study. Eur Respir J. 2012; 40: 436-41.
15. Lervy B, Wareham K, Cheung WY. Practice characteristics associated with audit activity: a medical audit advisory group survey. Br J Gen Pract. 1994; 44: 311-4.
16. Munck AP, Damsgaard JJ, Hansen DG, Bjerrum L, Søndergaard J. The APO method-a popular form of quality development in general practice. Ugeskr Laeger. 2002; 164: 5390-3.
17. Uso de antibióticos en España (Spanish). 2010. Ministerio de Sanidad,Política Social e Igualdad y Agencia Española de Medicamentos y Productos Sanitarios., http://www.aemps.gob.es/medicamentosUsoHumano/ observatorio/docs/antibioticos.pdf (accessed on 6 April 2015).
18. Miravitlles M, de la Roza C, Naberan K, et al. Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med. 2007; 101: 1753-60.
19. Miravitlles M, Moragas A, Hernández S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013; 144: 1571-7.
20. Price DB, Honeybourne D, Little P, et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir Med. 2004; 98: 17-24.
21. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial.. BMJ. 2009; 338: b1374.